RELMADA THERAPEUTICS, INC. (RLMD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US75955J4022
RELMADA THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -59.10 m USD |
| EBIT | -58.78 m USD |
| Net income | -57.39 m USD |
| Diluted EPS – continuing operations | -1.45 USD |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About RELMADA THERAPEUTICS, INC.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
More stocks
- Guangzhou Amsky Technology Co Ltd (300521.SZ)
- Bank of Marin Bancorp (BMRC)
- Eson Precision Ind Co Ltd (5243.TW)
- Ever Supreme Bio Technology Co. Ltd (6712.TWO)
- Zhejiang Cheng Yi Pharmaceutical Co Ltd (603811.SS)
- Ways Electron Co Ltd (605218.SS)
- FuJian YanJing HuiQuan Brewery Co Ltd (600573.SS)
- ATN International, Inc. (ATNI)
- ZRP Printing Group Co. Ltd. (301223.SZ)
- BECE Legend Group Co Ltd (000803.SZ)
- Jilin Joinature Polymer Co Ltd (688716.SS)
- Shanghai Hi-Road Food Technology Co. Ltd. (300915.SZ)
Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.